Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy
BACKGROUND: Overweight and obesity have a significant impact on the course and results of treatment of many diseases, including cancer. One of the modern types of antitumor therapy is immune checkpoint inhibitors. Taking into account the high effectiveness of immune checkpoint inhibitors for various...
| मुख्य लेखकों: | , , , , , , |
|---|---|
| स्वरूप: | लेख |
| भाषा: | English |
| प्रकाशित: |
Endocrinology Research Centre
2024-04-01
|
| श्रृंखला: | Ожирение и метаболизм |
| विषय: | |
| ऑनलाइन पहुंच: | https://www.omet-endojournals.ru/jour/article/view/13044 |
| _version_ | 1827121651860373504 |
|---|---|
| author | A. A. Glibka N. V. Mazurina E. A. Troshina K. A. Sarantseva G. Yu. Kharkevich M. V. Volkonskii A. R. Elfimova |
| author_facet | A. A. Glibka N. V. Mazurina E. A. Troshina K. A. Sarantseva G. Yu. Kharkevich M. V. Volkonskii A. R. Elfimova |
| author_sort | A. A. Glibka |
| collection | DOAJ |
| description | BACKGROUND: Overweight and obesity have a significant impact on the course and results of treatment of many diseases, including cancer. One of the modern types of antitumor therapy is immune checkpoint inhibitors. Taking into account the high effectiveness of immune checkpoint inhibitors for various types of tumors, it seems interesting to study the initial anthropometric data of patients and assess the possible influence of nutritional status on the development of endocrine immune-mediated adverse events.AIM: To compare groups of patients with different starting body mass index (BMI) before the first administration of the immune checkpoint inhibitors drug and analyze the risk of developing endocrine immune-mediated adverse events in the future.MATERIALS AND METHODS: The single-center study included 172 patients who were recommended antitumor therapy immune checkpoint inhibitors at the N.N. Blokhin National Medical Research Center of Oncology and Moscow City Oncology Hospital №62 in 2020–2022. Measurement of height and body weight with further calculation of BMI was carried out before the first administration of the drug immune checkpoint inhibitors.Depending on the subsequent occurrence of immune-mediated adverse events, patients were divided into groups: those with developed immune-mediated adverse events (any, cutaneous, thyroid) and those without immune-mediated adverse events (any, cutaneous, thyroid).RESULTS: According to the results of our study, in 38 patients (37.3%) out of 102, for whom data on the presence/absence of any immune-mediated adverse events were obtained, the following were recorded: thyropathies (n=13, 12.7%), skin lesions (n=13, 12.7%), gastrointestinal toxicity (n=7, 6.9%), hepatotoxicity (n=4, 3.9%), hypophysitis (n=2, 2%), nephritis (n=2, 2%), diabetes mellitus (DM) (n=1, 1%), hematological toxicity (n=1, 1%), pneumonitis (n=1, 1%), Guillain-Barré syndrome (n=1, 1%). At the same time, in most patients only one immune-mediated adverse event was encountered (n=31, 81.6%), two immune-mediated adverse events were detected significantly less frequently (n=7, 18.4%).When conducting a comparative analysis of groups of patients with developed immune-mediated adverse events, including dermatological ones, or their absence, a statistical trend in differences in BMI was obtained. Using ROC analysis, a BMI cut-off point was determined equal to 28.16 kg/m² for all immune-mediated adverse events and 25.39 kg/m² for skin immune-mediated adverse events, below which, contrary to the available data, the risk of developing immune-mediated adverse events increased, but the diagnostic sensitivity (DS) and diagnostic specificity (DS) turned out to be low.CONCLUSION: We identified a statistical trend in the risk of developing immune-mediated adverse events (primarily dermatological) with a lower BMI before the start of antitumor immunotherapy immune checkpoint inhibitors. More research is required to find a more reliable relationship. |
| first_indexed | 2024-04-24T08:36:49Z |
| format | Article |
| id | doaj.art-7e0ebbaa233b4fd4bd6bf97d481edf63 |
| institution | Directory Open Access Journal |
| issn | 2071-8713 2306-5524 |
| language | English |
| last_indexed | 2025-03-20T13:56:32Z |
| publishDate | 2024-04-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Ожирение и метаболизм |
| spelling | doaj.art-7e0ebbaa233b4fd4bd6bf97d481edf632024-09-11T16:17:54ZengEndocrinology Research CentreОжирение и метаболизм2071-87132306-55242024-04-01211425710.14341/omet1304411007Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapyA. A. Glibka0N. V. Mazurina1E. A. Troshina2K. A. Sarantseva3G. Yu. Kharkevich4M. V. Volkonskii5A. R. Elfimova6Endocrinology Research CentreEndocrinology Research CentreEndocrinology Research CentreNational Medical Research Center of Oncology named after. N.N. Blokhin; Russian National Research Medical University named after N.I. PirogovNational Medical Research Center of Oncology named after. N.N. BlokhinOncology Hospital №62Endocrinology Research CentreBACKGROUND: Overweight and obesity have a significant impact on the course and results of treatment of many diseases, including cancer. One of the modern types of antitumor therapy is immune checkpoint inhibitors. Taking into account the high effectiveness of immune checkpoint inhibitors for various types of tumors, it seems interesting to study the initial anthropometric data of patients and assess the possible influence of nutritional status on the development of endocrine immune-mediated adverse events.AIM: To compare groups of patients with different starting body mass index (BMI) before the first administration of the immune checkpoint inhibitors drug and analyze the risk of developing endocrine immune-mediated adverse events in the future.MATERIALS AND METHODS: The single-center study included 172 patients who were recommended antitumor therapy immune checkpoint inhibitors at the N.N. Blokhin National Medical Research Center of Oncology and Moscow City Oncology Hospital №62 in 2020–2022. Measurement of height and body weight with further calculation of BMI was carried out before the first administration of the drug immune checkpoint inhibitors.Depending on the subsequent occurrence of immune-mediated adverse events, patients were divided into groups: those with developed immune-mediated adverse events (any, cutaneous, thyroid) and those without immune-mediated adverse events (any, cutaneous, thyroid).RESULTS: According to the results of our study, in 38 patients (37.3%) out of 102, for whom data on the presence/absence of any immune-mediated adverse events were obtained, the following were recorded: thyropathies (n=13, 12.7%), skin lesions (n=13, 12.7%), gastrointestinal toxicity (n=7, 6.9%), hepatotoxicity (n=4, 3.9%), hypophysitis (n=2, 2%), nephritis (n=2, 2%), diabetes mellitus (DM) (n=1, 1%), hematological toxicity (n=1, 1%), pneumonitis (n=1, 1%), Guillain-Barré syndrome (n=1, 1%). At the same time, in most patients only one immune-mediated adverse event was encountered (n=31, 81.6%), two immune-mediated adverse events were detected significantly less frequently (n=7, 18.4%).When conducting a comparative analysis of groups of patients with developed immune-mediated adverse events, including dermatological ones, or their absence, a statistical trend in differences in BMI was obtained. Using ROC analysis, a BMI cut-off point was determined equal to 28.16 kg/m² for all immune-mediated adverse events and 25.39 kg/m² for skin immune-mediated adverse events, below which, contrary to the available data, the risk of developing immune-mediated adverse events increased, but the diagnostic sensitivity (DS) and diagnostic specificity (DS) turned out to be low.CONCLUSION: We identified a statistical trend in the risk of developing immune-mediated adverse events (primarily dermatological) with a lower BMI before the start of antitumor immunotherapy immune checkpoint inhibitors. More research is required to find a more reliable relationship.https://www.omet-endojournals.ru/jour/article/view/13044immune checkpoint inhibitorsimmune-mediated adverse eventsbody mass indexdestructive thyroiditishypophysitisdiabetes mellitus |
| spellingShingle | A. A. Glibka N. V. Mazurina E. A. Troshina K. A. Sarantseva G. Yu. Kharkevich M. V. Volkonskii A. R. Elfimova Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy Ожирение и метаболизм immune checkpoint inhibitors immune-mediated adverse events body mass index destructive thyroiditis hypophysitis diabetes mellitus |
| title | Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy |
| title_full | Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy |
| title_fullStr | Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy |
| title_full_unstemmed | Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy |
| title_short | Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy |
| title_sort | body mass index as a possible predictor of the development of endocrine immune mediated adverse events during immune checkpoint inhibitors therapy |
| topic | immune checkpoint inhibitors immune-mediated adverse events body mass index destructive thyroiditis hypophysitis diabetes mellitus |
| url | https://www.omet-endojournals.ru/jour/article/view/13044 |
| work_keys_str_mv | AT aaglibka bodymassindexasapossiblepredictorofthedevelopmentofendocrineimmunemediatedadverseeventsduringimmunecheckpointinhibitorstherapy AT nvmazurina bodymassindexasapossiblepredictorofthedevelopmentofendocrineimmunemediatedadverseeventsduringimmunecheckpointinhibitorstherapy AT eatroshina bodymassindexasapossiblepredictorofthedevelopmentofendocrineimmunemediatedadverseeventsduringimmunecheckpointinhibitorstherapy AT kasarantseva bodymassindexasapossiblepredictorofthedevelopmentofendocrineimmunemediatedadverseeventsduringimmunecheckpointinhibitorstherapy AT gyukharkevich bodymassindexasapossiblepredictorofthedevelopmentofendocrineimmunemediatedadverseeventsduringimmunecheckpointinhibitorstherapy AT mvvolkonskii bodymassindexasapossiblepredictorofthedevelopmentofendocrineimmunemediatedadverseeventsduringimmunecheckpointinhibitorstherapy AT arelfimova bodymassindexasapossiblepredictorofthedevelopmentofendocrineimmunemediatedadverseeventsduringimmunecheckpointinhibitorstherapy |